Anticoagulants: A Global Strategic Business Report
San Jose, CA (PRWEB) October 30, 2008
The unmet medical needs of available anticoagulants offer ample scope for development in the world anticoagulants market. Continuous research and development is expected to result in novel therapies with superior therapeutic efficiency, and minimum side effects. These advanced therapeutics offer promising market prospects. Exanta, for instance, represents a cutting edge direct thrombin inhibitor that flaunts the potential to kindle demand patterns, dethrone warfarin's dominance, and challenge the supremacy of low molecular weight heparins. Identification of new indications for existing, and emerging therapies is expected to help open up brighter prospects for further growth.
Factor Xa inhibitors (oral and injectable) and direct thrombin inhibitors (oral and injectable) are among the new class of thrombin antagonists that are being evaluated for both existing as well as newer indications. Development of products for specific market niches, like, anticoagulation therapies for ischemic stroke, is additionally expected to result in expanded opportunities. Patent expiries of drugs like "Coumadin" offer a lucrative business case for generic drug manufacturers. Favorable demographic patterns, like the rapidly aging world population is expected to drive demand patterns, given the tendency of aging individuals to develop various venous and arterial complications.
The United States dominates the world anticoagulants market, with a share of nearly 50%, as stated by Global Industry Analysts, Inc. Strong double digit growth is expected to stem from the injectable anticoagulants market, with the United States setting the pace of growth with projected CAGR in excess of 15.1% over the period of 2000 through 2010. Market for injectable anticoagulants is dominated by low molecular weight heparin (LMWH). Strong growth in LMWH market is expected to push sales of injectable anticoagulants to US$6.6 billion by 2010.
Major market participants profiled include AstraZeneca PLC, Barr Laboratories Inc., Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline plc, Mitsubishi Tanabe Pharma Corporation, Pfizer Inc., and Sanofi-Aventis.
The report titled "Anticoagulants: A Global Strategic Business Report" published by Global Industry Analysts, Inc., provides a comprehensive review of market trends, drivers, issues, challenges, and research and development activities. Richly annotated with authoritative, and unbiased commentaries, and hard-to-find statistical facts, the report provides unequivocal views on future potential while throwing light on the prevailing climate in key regional markets. Product markets analyzed in the report include Oral, and Injectable (Unfractionated Heparin, and Low Molecular Weight Heparin). Latent demand patterns in product markets are quantified across major geographic market verticals including the United States, Japan, France, Germany, United Kingdom, Italy, and Spain, among others for the period 2000-2015. Also provided in the report is an enumeration of recent mergers, acquisitions, and other strategic industry activities.
For more details about this research report, please visit
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs more than 700 people worldwide and publishes more than 880 full-scale research reports each year. Additionally, the company also offers a range of more than 60,000 smaller research products including company reports, market trend reports and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Web Site http://www.StrategyR.com/